Dual function antibody targeting αvβ3 and PD-L1 provide a promising strategy for solid tumor therapy
The dual function antibody targeting both αvβ3 and PD-L1 holds the potential to reverse immune evasion and exhibit synergistic anti-tumor effects, offering a promising therapeutic strategy for the treatment of solid tumor.
Authors
- Genbei Wang (ORCID: https://orcid.org/0000-0001-6341-5201)
- Huaibin Mu
- Ruijia Hao
- Guixia Li (ORCID: https://orcid.org/0000-0003-3948-7488)
- Yibo Wang (ORCID: https://orcid.org/0000-0003-1262-4497)
- Xuemin Zheng
- Yuxin Bi
- Ruijing Huang
- Xiaohui Ma
- Jian Li
- Shuiping Zhou
- Liuli Wang
- Jin Han
- Yanchen Yin
- Wenlei Li
- Yan Yu
Institutions
- Tasly Holding Group (China) (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-12
- DOI
- https://doi.org/10.3389/fimmu.2025.1691774
- Primary Topic
- Cell Adhesion Molecules Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00